Vanessa
Roldan Schilling
Catedraticos de Universidad Vinculados H.V.Arrixaca
Rocio
Gonzalez-Conejero Hilla
Profesor Titular de Universidad Vinculado H.U.M.M.
Publicaciones en las que colabora con Rocio Gonzalez-Conejero Hilla (37)
2020
-
Pilot study on the role of circulating mirnas for the improvement of the predictive ability of the 2mace score in patients with atrial fibrillation
Journal of Clinical Medicine, Vol. 9, Núm. 11, pp. 1-11
2019
-
Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals
Clinical Pharmacology and Therapeutics, Vol. 105, Núm. 6, pp. 1477-1491
2018
-
MiR-146a Regulates Neutrophil Extracellular Trap Formation That Predicts Adverse Cardiovascular Events in Patients with Atrial Fibrillation
Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 38, Núm. 4, pp. 892-902
-
MiR-146a deficiency in hematopoietic cells is not involved in the development of atherosclerosis
PLoS ONE, Vol. 13, Núm. 6
-
Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation
European Journal of Clinical Investigation, Vol. 48, Núm. 6
2017
2016
-
Genotype-guided therapy improves initial acenocoumarol dosing: Results from a prospective randomised study
Thrombosis and Haemostasis, Vol. 115, Núm. 1, pp. 117-125
-
MiRNA-based regulation of hemostatic factors through hepatic nuclear factor-4 alpha
PLoS ONE, Vol. 11, Núm. 5
2014
-
Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment
Pharmacogenomics, Vol. 15, Núm. 7, pp. 987-996
-
Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation
Thrombosis and Haemostasis, Vol. 112, Núm. 4, pp. 781-788
2013
-
Creating a genotype-based dosing algorithm for acenocoumarol steady dose
Thrombosis and Haemostasis, Vol. 109, Núm. 1, pp. 146-153
-
Novel Associations of VKORC1 Variants with Higher Acenocoumarol Requirements
PLoS ONE, Vol. 8, Núm. 5
2012
-
miR-133a regulates Vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1), a key protein in the Vitamin K cycle
Molecular Medicine, Vol. 18, Núm. 11, pp. 1466-1472
2010
-
Influence of the F12-4 C>T polymorphism on hemostatic tests
Blood Coagulation and Fibrinolysis, Vol. 21, Núm. 7, pp. 632-639
-
Pharmacogenetics of acenocoumarol in patients with extreme dose requirements
Journal of Thrombosis and Haemostasis, Vol. 8, Núm. 5, pp. 1012-1017
-
Study of 18 functional hemostatic polymorphisms in mucocutaneous bleeding disorders
Annals of Hematology, Vol. 89, Núm. 11, pp. 1147-1154
-
Synergism between factor XII -4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction
Thrombosis and Haemostasis
2009
-
Antithrombin Cambridge ll (A384S) supports a role for antithrombin deficiency in arterial thrombosis
Thrombosis and Haemostasis, Vol. 101, Núm. 3, pp. 483-486
-
Implications of pharmacogenetics for oral anticoagulants metabolism
Current Drug Metabolism, Vol. 10, Núm. 6, pp. 632-642
-
Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy
Blood, Vol. 113, Núm. 20, pp. 4977-4979